Recent Progress in the Pharmacotherapy of Alzheimer's Disease

Drugs Aging. 2017 Nov;34(11):811-820. doi: 10.1007/s40266-017-0499-x.

Abstract

Alzheimer's disease is the most common major neurocognitive disorder with substantial social and economic impacts. This article is an update on current pharmacotherapy, advancements in biomarker use, and drugs in the pipeline for this disease. To date, no new drug has qualified to be added to the current therapeutic arsenal comprising cholinesterase inhibitors and the NMDA receptor antagonist memantine. Drugs in the pipeline include symptomatic therapies that are neurotransmitter-based, but mostly disease-modifying therapies. The latter have yielded disappointing results by focusing mainly on the two pathophysiological hallmarks of Alzheimer's disease: Aβ amyloid deposits and tau protein aggregates forming neurofibrillary tangles. These unsuccessful trials may have resulted from studying these drugs 'too late' relative to Alzheimer's disease onset, in addition to focusing only on the amyloid cascade. In fact, Alzheimer's disease is a complex multifactorial disease. Combining different biomarkers might enhance our ability to identify those patients most at risk of developing the disease, and better predict their conversion rates. Furthermore, adopting an integrative treatment approach by targeting additional pathophysiological pathways in Alzheimer's disease such as inflammation and oxidative stress could be the key to better outcomes in Alzheimer's disease pharmacotherapy research.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / metabolism
  • Amyloid beta-Peptides / metabolism
  • Biomarkers / metabolism
  • Cholinesterase Inhibitors / therapeutic use*
  • Excitatory Amino Acid Antagonists / therapeutic use*
  • Humans
  • Memantine / therapeutic use*
  • Molecular Targeted Therapy
  • Oxidative Stress / drug effects*
  • Receptors, N-Methyl-D-Aspartate / metabolism

Substances

  • Amyloid beta-Peptides
  • Biomarkers
  • Cholinesterase Inhibitors
  • Excitatory Amino Acid Antagonists
  • Receptors, N-Methyl-D-Aspartate
  • Memantine